Avelas, AristaMD, and Synthorx recognized as Xconomy’s San Diego Life Science Startups to Watch in 2016

San Diego continues to be a hot bed for life science startups that are advancing technological and healthcare innovation. Within this growing community, several companies have proven to be early stand-outs in 2016 and gained recognition in an article from Xconomy featuring 12 San Diego Life Sciences Startups to Watch. Three COI companies, Avelas, AristaMD, and Synthorx, were included in that feature.

Avelas recently initiated enrollment for a clinical trial at the UC San Francisco for the company’s in vivo surgical breast cancer diagnostic agent, AVB-620. This technology is being developed to help surgeons determine cancerous tissue from non-cancerous tissue in real-time during surgery.

AristaMD enables physician-to-physician consults that are proven to reduce unnecessary referrals and related costs. Recently, the company entered into a licensing agreement with the UC San Francisco, granting AristaMD rights to use physician-referral decision-making guidelines.

Synthorx is using synthetic biology to discover and develop novel therapeutics, diagnostics and vaccines. The company announced last year that they are now able to make full-length synthetic proteins using their expanded DNA alphabet.

Read the full Xconomy article here.